B cell lymphoma survival

B-cell lymphomas are solid tumors that arise from B cells. Includes Hodgkin lymphoma and non-Hodgkin lymphoma. There are many types of Hodgkin's lymphoma, including classical Hodgkin's lymphoma and nodular lymphocyte-predominant Hodgkin's lymphoma, which are now considered to be tumors originating from B cells. The five most common B-cell non-Hodgkin's lymphomas are diffuse large B-cell lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma (MALT), small lymphocytic lymphoma/chronic lymphocytic leukemia, and mantle cell lymphoma (MCL), accounting for three-quarters of non-Hodgkin's lymphoma. The prognosis and treatment of B-cell lymphoma depend on the specific type of lymphoma and its stage and grade.

B-cell lymphoma survival According to the different clinical behaviors, B-cell lymphoma is divided into indolent lymphoma and aggressive lymphoma. Indolent lymphomas usually develop slowly, with many years of stable disease and long-term survival, but they are incurable. Aggressive lymphomas usually require more aggressive treatment, but cure is possible. The prognosis and treatment of B-cell lymphoma depend on the specific type of lymphoma and its stage and grade. In 1993, Shipp et al. proposed the International Prognostic Index (IPI) for NHL, which divided the prognosis of NHL into four categories: low risk, low-intermediate risk, high-intermediate risk, and high risk. The estimated 5-year overall survival rates were 73%, 51%, 43%, and 26%, respectively. Age over 60 years old, stage III or IV, more than one extranodal lesion, need to be bedridden or need care from others, and elevated serum LDH are 5 IPIs with poor prognosis. The prognosis of NHL can be judged based on the number of IPIs the patient has.

Incidence: In European and American countries, the incidence of DLBCL accounts for about 31% of non-Hodgkin's lymphoma (NHL), and in Asian countries it accounts for more than 40% of NHL, but there is a lack of accurate statistical data on the incidence in China. DLBCL can occur at any age but is more common in the elderly.

The median age of onset is 60-64 years old, with slightly more males than females. The typical clinical manifestation is a rapidly enlarging painless mass. About one-third of patients have B symptoms, and the incidence of bone marrow involvement is 16%. The tumor mainly occurs in the lymph nodes, and more than 30% of patients present with localized extra-lymph node lesions as the first lesion. Extranodal lesions are common in the gastrointestinal tract, bones, and central nervous system.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma in adults, accounting for about 30-40%. It is more common in middle-aged and elderly people, with the majority in China aged 40-50. In recent years, with the advent of new drugs, especially Rituximab, coupled with the continuous improvement of treatment plans and the comprehensive application of hematopoietic stem cell transplantation.

This type of lymphoma is very effective in treatment and more than half of cases can be cured. It should be emphasized that the treatment effect of patients is affected by many factors, and standardized stratified treatment should be carried out, and one plan cannot "cure" all patients. Combination chemotherapy has gradually transformed DLBCL from an incurable disease to a potentially curable disease.